The effect of latanoprost on intraocular pressure during 2 years of treatment

Survey of Ophthalmology

Volumn 47, Issue 4 SUPPL. 1, 2002, Pages

  Hedman, Katarina ^a,b   Watson, Peter G ^c   Alm, Albert ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Thermo Fisher Scientific   (United States)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Intraocular pressure; Latanoprost; Ocular hypertension; Open angle glaucoma; Prostaglandin; Timolol

Indexed keywords

LATANOPROST; TIMOLOL;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EYE DISEASE; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RISK; SURVIVAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0036669288     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6257(02)00301-6     Document Type: Article

References (31)

1. The advanced glaucoma intervention study (AGIS). 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators Am J Ophthalmol. 130:2000;429-440.
2. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 12:1998;498-505.
3. Alm A., Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 102:1995;1743-1752.
4. Alm A., Villumsen J. PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers. Arch Ophthalmol. 109:1991;1564-1568.
5. Alm A., Widengard I. Latanoprost. experience of 2-year treatment in Scandinavia Acta Ophthalmol Scand. 78:2000;71-76.
6. Boger W.P. 3rd, Puliafito C.A., Steinert R.F., Langston D.P. Long-term experience with timolol ophthalmic solution in patients with open-angle glaucoma. Ophthalmology. 85:1978;259-267.
7. Crawford K., Kaufman P.L. Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of Uveoscleral outflow by prostaglandin F2 alpha. Arch Ophthalmol. 105:1987;1112-1116.
8. Gabelt B.T., Kaufman P.L. Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res. 49:1989;389-402.
9. Gandolfi S.A. Restoring sensitivity to timolol after long-term drift in primary open- angle glaucoma. Invest Ophthalmol Vis Sci. 31:1990;354-358.
10. Hedman K., Alm A. A pooled data analysis of three randomised, double-masked six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol. 2:2000;94-104.
11. Kobelt-Nguyen G., Gerdtham U.G., Alm A. Costs of treating primary open-angle glaucoma and ocular hypertension. a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States J Glaucoma. 7:1998;95-104.
12. Lee T.L. Identification of prognostic factors related to survival time. Lee T.L. Statistical Methods for Survival Data Analysis. 1992;243-279 Wiley-Interscience, New York. ed 2,
13. Lee T.L. Nonparametric methods of estimating survival functions. Lee T.L. Statistical Methods for Survival Data Analysis. 1992;66-101 Wiley-Interscience, New York. ed 2,
14. MacMahon S., Peto R., Cutler J.et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure. prospective observational studies corrected for the regression dilution bias Lancet. 335:1990;765-774.
15. Migdal C., Gregory W., Hitchings R. Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology. 101:1994;1651-1656. discussion 1657.
16. Milliken G.A., Johnson D.E. Analyzing split-plot and certain repeated measures experiments with unbalanced and missing data. Milliken G.A., Johnson D.E. Analysis of Messy Data. 1992;377-407 Chapman & Hall, New York.
17. Nilsson S.F., Samuelsson M., Bill A., Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey. Exp Eye Res. 48:1989;707-716.
18. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res. 67:1998;179-191.
19. Quigley H.A., Tielsch J.M., Katz J., Sommer A. Rate of progression in open-angle glaucoma estimated from cross-sectional prevalence of visual field damage. Am J Ophthalmol. 122:1996;355-363.
20. Ray W.A., O'Day D.M., Head W.S., Robinson R. Statistical analysis for experimental models of ocular disease. continuous response measures Curr Eye Res. 4:1985;585-597.
21. Resul B., Stjernschantz J., No K.et al. Phenyl-substituted prostaglandins. potent and selective antiglaucoma agents J Med Chem. 36:1993;243-248.
22. Rouland J.F., Hågå A., Bengtsson S.et al. What triggers change in therapy? Jönsson B., Krieglstein G. Primary Open-angle Glaucoma. Differences in International Treatment Patterns and Costs. 1998;163-169 ISIS Medical Media Ltd, Oxford.
23. Schachtschabel U., Lindsey J.D., Weinreb R.N. The mechanism of action of prostaglandins on uveoscleral outflow. Curr Opin Ophthalmol. 11:2000;112-115.
24. Sommer A., Tielsch J.M., Katz J.et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol. 109:1991;1090-1095.
25. Stjernschantz J., Resul B. Phenyl substituted prostaglandin analogs for glaucoma treatment. Drugs Future. 8:1992;691-704.
26. Toris C.B., Camras C.B., Yablonski M.E. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 100:1993;1297-1304.
27. Watson P., Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology. 103:1996;126-137.
28. Watson P.G., Barnett M.F., Parker V., Haybittle J. A 7 year prospective comparative study of three topical beta blockers in the management of primary open angle glaucoma. Br J Ophthalmol. 85:2001;962-968.
29. Watson P.G. Latanoprost. Two years experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology 105:1998;82-87.
30. Wistrand P.J., Stjernschantz J., Olsson K.et al. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 41(Suppl 2):1997;S129-S138.
31. Ziai N., Dolan J.W., Kacere R.D., Brubaker R.F. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 111:1993;1351-1358.